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Evaluation of a macrophage attenuated isolate of'PRRSV as a
vaccine for porcine reproductive and respiratory syndrome virus
C.D. Nelson, R.R. Rowland, D.H. Zeman and D.A. Benfield
Department of Veterinary Science

SDSU

SWINE 2001-19

PRRS
continues
to
be the
most
economically important disease of swine. While
the acute reproductive disease is still prevalent,
chronic or endemic PRRS in nursery and
grow/finish pigs is a major problem confronting
most swine producers. Post-weaning problems
in these herds include a 50-85% reduction in
growth
rates;
a
10-30%
increase
in
unmarketable pigs; and a 10-25% increase in
post-weaning mortality. Popular protocols .to
manage PRRSV infections include breeding
herd stabilization; elimination of seronegative
sub-populations of susceptible gilts; nursery
depopulation;
and
more
recently mass
vaccination/unidirectional pig flow in the
grow/finish unit. Most of these control programs
also use the commercial modified-live vaccines,
RespPRRS® or PrimePac PRRS® as part of the
management protocol.

pregnant animals. If replication in macrophages
accounts for the undesirable traits of modifiedlive PRRSV vaccines, then a vaccine virus that
is "macrophage-attenuated" (reduced or no
replication in macrophages) would be safer.
This vaccine can be produced in the
conventional fashion; would be more economical
to produce than molecular or subunit vaccines,
and would avoid the loss of structural antigens
(antigenicity), which is a problem with subunit
and killed vaccines. The purpose of this study
was to test two PRRSV isolates that replicate
poorly in porcine alveolar macrophages, for
safety and efficacy in young pigs and pregnant
animals.
The goal of this project is to determine if an
isolate of PRRSV, that has been modified by
serial passage in monkey kidney cells (MARC145) and replicates at very low levels in porcine
alveolar macrophages, is avirulent for pigs and
pregnant gilts.
The original aims were to
determine if this macrophage-attenuated isolate
replicates in neonatal pigs, induces viremia
and/or lesions and results in seroconversion.

Although modified-live PRRSV vaccines are
useful management tools, producers and
veterinarians are mindful of their undesirable
traits and disadvantages, which include:
induction of viremia; infection of fetuses in
vaccinated pregnant animals; transmission of
vaccine virus to naive pigs; persistence of
vaccine virus in pigs; shedding of vaccine virus
in semen; and the potential for vaccine virus to
revert to virulence. These problems explain the
recent popularity of using autogenous and
commercial (PRRomi~e ™) killed vaccines, which
are safer than modified-live vaccines. However,
many of the problems •inherent to modified-live
PRRSV vaccines are related to the ability of
vaccine viruses to imitate virulent field viruses
and replicate in macrophages, which results in:
1) dissemination of the virus in the pig;
2) shedding
through
bodily
secretions;
3) transplacental
transmission;
and
Both
4) persistence in lymphoid tissue.
RespPRRS® and PrimePac PRRS® replicate in
pig alveolar macrophages and this may p;irtially
explain why vaccinated pigs develop viremia
and shed virus to contacts. It may also explain
why the virus is able to reach the fetus in

Experimental Procedures
Does
the
macrophage
Objective 1:
attenuated isolate of PRRSV 23983 replicate in
neonatal pigs, induce viremia and/or lesions and
cause seroconversion? The passage-136
(P136) isolate of PRRSV 23983 does · not
replicate well in alveolar macrophages, but does
grow to high titers in the MARC-145 cells to
which the virus is adapted. Thus, we compared
the virulence of the parental wild-type virus
passage-6 (P6) and the macrophage-attenuated
P136 to the two commercial modified-live virus
vaccines (RespPRRS® and PrimePac PRRS®).
In these experiments, 58, 6-day old gnotobiotic
pigs from three litters were inoculated either
intranasally or intramuscularly with the P6,
P136, commercial vaccines or mock inoculum.
Each virus was adjusted to result in a dosage of
4
10 tissue culture infectious doses (TCID 50 ) per
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2 ml of inoculum. Piglets were observed daily
for clinical signs and rectal temperatures were
recorded for 14 days post inoculation (dpi) with
virus. After 2 weeks, pigs were euthanized,
examined at post-mortem for gross lesions and
various
tissues
[lung,
lymph
nodes
(trachealbronchial, mandibular, mesenteric, and
external inguinal), salivary gland, heart, thymus,
spleen, liver and tonsil] were removed for virus
isolation and light microscopy examination for
microscopic lesions. Serum was also collected
at 0, 1, 3, 5, 7, 10 and 14 dpi for serology and
virus isolation.

There was no significant variation in daily
temperatures between the inoculated groups of
pigs. Temperatures were highest in the P6
inoculated pigs between 7 to 14 dpi. The rectal
temperatures in the P136 pigs tended to be
similar to those of pigs given the modified-live
vaccine viruses.
Dyspnea (severe, labored breathing) was
only observed in pigs receiving the P6 virulent
isolate of PRRSV. This condition was principally
observed from 10 to 18 dpi in pigs given P6
intranasally and in a one pig at 15 dpi given the
P6 intramuscularly.

Results
Pigs given the P6 PRRSV isolate had
lesions typical of PRRS induced interstitial
pneumonia in 9/10 animals and virus was
isolated from all tissues sampled in 10/1 O pigs.
Less severe lesions were observed in the lungs
of 1/10 pigs inoculated with PrimePac PRRS®
and 5/15 given RespPRRS®. Similar to the
P6 inoculated pigs, vaccine virus was isolated
from all pigs (10/10 and 13/13 pigs,
respectively).
In contrast, virus was only
isolated from 1/13 pigs given the macrophageattenuated isolate and none of these pigs had
lesions. Two mock-inoculated pigs also had
early clinical signs of lethargy and lacrimation.
No lesions were observed and no virus was
isolated from tissues of the mock-inoculated pigs
(see Table 1).

Objective 1:
Does
the
macrophage
attenuated isolate of PRRSV 23983 replicate in
neonatal pigs, induce viremia and/or lesions and
cause seroconversion?
Our goal was to
determine if the loss of the ability of PRRSV to
replicate in alveolar macrophages would result
in a virus that is less virulent in pigs than the
current modified-live vaccines (RespPRRS® and
PrimePac PRRS®). Sequential passage of the
23983 PRRSV on MARC-145 cells resulted in a
reduction in the yield of PRRSV in alveolar
macrophages.
Fifty-four passages of the
PRRSV resulted in only a 10-fold reduction in
virus yield compared to the virulent PS.
Similarly, there was a 100- and 1000-fold
reduction in the yield of PRRSV from passages
P94 and P136, respectively (Figure 1).

Seroconversion was monitored using the
commercial
enzyme-linked
immunosorbent
assay (ELISA) at O and 14 dpi. The pigs given
the P6 inoculum either intranasally or intraIn
muscularly all seroconverted by 14 dpi.
contrast, only 50% and 30% of the pigs given
PrimePac
PRRS®
and
RespPRRS®
intramuscularly seroconverted by 14 dpi.
A
lower number of pigs receiving PrimePac
PRRS®
and
RespPRRS®
intranasally
seroconverted at this time, 25% and 20%,
respectively.
None of the P136 or mockinoculated pigs was seropositive at 14 dpi.

Comparison of the virulence of the
macrophage-attenuated P136 isolate to the
virulent P6 isolate of the 23983 PRRSV and the
commercial modified-live viral vaccines was
done using 58 gnotobiotic pigs randomly
assigned to experimental groups indicated in
Table 1.
Daily clinical scores varied within
experimental groups.
Surprisingly, the pigs
given PrimePac PRRS® intranasally had the
most severe clinical signs between 4 and 8 dpi,
after which the P6 group had the most
prominent clinical signs from 8 to 17 dpi.
Clinical signs included lethargy, inappetance,
diarrhea, eyelid edema and occasional
lacrimation. Milder clinical signs were observed
in the P136 pigs for the first 5 dpi. Clinical signs
of lethargy and lacrimation were also observed
in 2/10 mock-infected pigs. In general, the P136
pigs had fewer and milder clinical signs of
PRRSV compared to the other virus infected
pigs.

Significance of results from Obiective 1.
The above results indicate that the P136
macrophage-attenuated isolate is less virulent in
pigs than either the P6 wild type or the
commercial modified-live vaccine viruses. This
is indicated by the less severe clinical signs, lack
of febrile response and absence of lesions
in pigs
inoculated with
the
observed
P136 PRRSV. The commercial vaccines did
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the other virus isolates. Thus, these results
indicate that macrophages do play a significant
role in the pathogenesis of PRRSV and that a
macrophage-attenuated isolate of PRRSV is
less virulent in young pigs. It was disappointing
that the P136 isolate did not result in
seroconversion of the pigs at 14 dpi indicating
that this attenuated virus may be too avirulent to
induce an immune response.

replicate extensively in the gnotobiotic pigs and
virus was isolated from most tissues of these
pigs regardless of the route of inoculation.
However, the P136 virus was recovered from
the lung of only one pig inoculated
intramuscularly indicating that there is still rare
potential for reversion to virulence of the P136
isolate.
There is probably less risk of
transmission considering the lack of recoverable
virus from tissues of the P136 pigs compared to

TABLE 1. SUMMARY OF RESULTS FOR GNOTOBIOTIC PIGS INOCULATED
WITH P6, P136, RESPPRRS® AND PRIMEPAC PRRS® VIRUSES
Number of Number of pigs
Number of
Number of pigs
Route of
pigs in
with clinical
pigs with lung
positive for virus
RRPS virus
inoculation
group
disease
lesions
isolation (ELISA)
P6
intranasal
5
5/5
5/5
5/5 (5/5)
intramuscular
5
5/5
4/5
5/5 (5/5)
P136
intranasal
6
1/6
0/6
0/6 (0/6)
intramuscular
7
5/7
0/7
1/7 (0/7)
Prime-Pac
Intranasal
4
2/4
0/4
4/4 (1/4)
6/6 (ND)
intramuscular
6
6/6
1/6
RespPRRS
intranasal
5
5/5
5/5
5/5 (1/5)
10
6/10
0/10
10/10 (3/10)
intramuscular
Mock
intranasal
4
0/4
0/4
0/4 (0/4)
intramuscular
6
2/6
1/6
0/6 (0/6)
Numbers in parenthesis in the last column indicate the number of pigs positive for antibodies by
ELISA/number of pigs inoculated with virus.
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Figure 1. Replication of various passages of the 23983 PRRS virus on
alveolar macrophages. Note that each successive passage of the virus in
MARC-145 cells resulted in a reduction or attenuation of the virus yield in
porcine alveolar macrophages.
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